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Background: Previous research has shown variation in the effects of patient factors, including hepatic
necroinflammatory activity, on liver stiffness measurement (LSM). This prospective study attempts to identify
explanatory factors for LSM in patients with chronic hepatitis C (CHC) using acoustic radiation force impulse (ARFI)
technology.
Methods: A cohort of 127 Taiwanese patients with CHC underwent ARFI LSM and immediate percutaneous liver
biopsy. This study compares the concurrent diagnostic performances of LSM and FibroTest using receiver operating
characteristic (ROC) curves. Three multiple linear regression models were used to evaluate the significance of
concurrent patient factors in explaining LSM.
Results: To classify METAVIR fibrosis (F) stages, the areas under ROC curves (AUCs) were ARFI LSM, 0.847 (95%
confidence interval (CI), 0.779-0.914) and FibroTest, 0.823 (95% CI, 0.748-0.898), for F1 versus F2-4; ARFI LSM, 0.902
(95% CI, 0.835-0.970) and FibroTest, 0.812 (95% CI, 0.735-0.888), for F1-2 versus F3-4; ARFI LSM, 0.831 (95% CI,
0.723-0.939) and FibroTest, 0.757 (95% CI, 0.648-0.865), for F1-3 versus F4. After adjusting for other demographic and
biological covariates, biochemical and histological necroinflammatory factors consistently explained LSM. Factors
included serum alanine aminotransferase (ALT)/upper limit of normal (ULN) categories (model R2 = 0.661, adjusted
R2 = 0.629), ActiTest A scores (R2 = 0.662, adjusted R2 = 0.636), and METAVIR activity (A) grades (R2 = 0.651, adjusted
R2 = 0.620). METAVIR F stages, body mass index, and platelet count were also independently associated with LSM.
Necroinflammatory degrees, including ALT/ULN, ActiTest A scores, and METAVIR A grades, explained the false
positivity of liver fibrosis staging using ARFI LSM.
Conclusions: The degree of hepatic necroinflammatory activity independently and significantly exaggerated liver
fibrosis evaluation using ARFI LSM. However, comparisons with concurrent FibroTest indicate that ARFI LSM may be
a promising alternative, or adjunctive single indicator, for liver fibrosis evaluation in patients with CHC.
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Hepatitis C virus (HCV) infection is a leading cause of cir-
rhosis and hepatocellular carcinoma (HCC) worldwide [1].
In the current era of antiviral and antifibrotic treatments,
clinical and research demands are increasing significantly
worldwide for noninvasive surveillance methods for liver
fibrosis. These methods are necessary to evaluate the pro-
gression and regression of liver fibrosis [2-6].
Recent investigations have proposed liver stiffness
measurement (LSM) using acoustic radiation force
impulse (ARFI) elastography as a novel, reliable, and ac-
curate noninvasive solution for evaluating liver fibrosis
[7-15]. However, the cutoff variability in previous studies
may be the result of a limited number of samples with
diverse hepatitis etiologies and variable sample charac-
teristics, including demographic and biological covari-
ates, ethnicity, and prolonged intervals between liver
biopsy and LSM. In several of these studies, the time
intervals between biopsy and LSM were as long as 6 to
15 months [8,12,13]. These may have affected the LSM
results because of potential histological progression and
the dynamic fibrogenic process.
Although previous studies [7,8,10,12-15] have imple-
mented concurrent FibroScan (Echosens, Paris, France)
and ARFI, few studies [8,9] have compared [16] the diag-
nostic performances or discrimination capabilities of
ARFI and FibroTest (BioPredictive, Paris, France) in
evaluating liver fibrosis. Local LSM spectra using ARFI
technology are still lacking for Taiwanese patients with
chronic hepatitis C (CHC).
In addition to several factors related to the stiffness
measurement itself [14,17-19], several patient factors,
including hepatic necroinflammatory activity [12,13,15,
20-30], cholestasis [31,32], and cardiac congestion [33],
affect the LSM values in liver fibrosis evaluation.
Therefore, independent significant explanatory patient
factors should be evaluated comprehensively with cau-
tion when interpreting or fine-tuning the results of
ARFI LSM. However, previous studies have shown
variation in the effects of patient factors, including
hepatic necroinflammatory activities, on LSM using
FibroScan or ARFI [12,13,28,32]. Despite the wide use
of hepatic elastography, few studies [12,29,30] have
correlated ARFI LSM with concurrent histological
steatosis and necroinflammatory categories, including
the METAVIR activity (METAVIR A) grades, and
not merely blood test results. Few studies have mea-
sured the necroinflammatory degrees using ActiTest
(BioPredictive, Paris, France) [34].
To date, clinically applicable noninvasive tests do not
focus on the exact staging of disease, but rather on div-
iding patients into categories of milder versus more sig-
nificant fibrosis and cirrhosis [5]. The adjusted effects of
METAVIR fibrosis (METAVIR F) stages on ARFI LSM,and the potential limitations of ARFI LSM (especially
the false positivity in liver fibrosis staging) also have yet
to be fully elucidated.
This prospective study examines the contributions of
concurrent patient factors, and especially the histo-
logical covariates, to ARFI LSM. This study also exam-
ines the adjusted effects of METAVIR F stages on
ARFI LSM, with the purpose of evaluating diagnostic
performance using the simple and noninvasive single
indicator ARFI LSM as compared with concurrent
FibroTest. Finally, this study identifies the optimal real
time ARFI LSM cutoff values for liver fibrosis staging
in Taiwanese patients with CHC.Methods
Patients
From November 2010 to October 2011, a cohort of 142
consecutive Taiwanese patients participated in this pro-
spective, operator-blind study. The participants were re-
ferred to the liver center for percutaneous liver biopsy
prior to the initiation of standard of care (SOC) for
CHC. This study defines CHC as positive serum anti-
HCV antibody (Abbott Laboratories, Abbott Park, Illi-
nois, USA) for more than six months with the presence
of serum HCV RNA (Cobas Amplicor HCV Monitor
2.0; Roche Diagnostics, Branchburg, New Jersey, USA).
Five patients refused, or were contraindicated for, per-
cutaneous liver biopsy. Thus, a total of 137 patients
underwent percutaneous liver biopsy within one hour of
receiving blood tests (including those for FibroTest) and
stiffness measurements, preceded by three hours of fast-
ing [35].
Patients with any of the following conditions or history
were excluded from the sample: interferon or nucleos(t)
ide analogue treatment, exposure to hepatotoxic drugs or
chemicals, primary biliary cirrhosis, primary sclerosing
cholangitis, Wilson’s disease, autoimmune hepatitis, alco-
holic liver disease (ALD), hepatitis B virus (HBV) coinfec-
tion, human immunodeficiency virus (HIV) coinfection,
liver abscess, acute hepatitis, extrahepatic cholestasis
[31,32], severe hemolysis, Gilbert's syndrome with high
unconjugated hyperbilirubinemia, autoimmune disorders,
myeloproliferative disorders, thalassemias, schistosomiasis,
major abdominal surgery, cardiac congestion [33], blood
product transfusion within the previous 30 days, preg-
nancy, liver cancer, serum creatinine higher than 221
umol/L (2.5 mg/dL), hepatic encephalopathy, refractory
ascites [36], and variceal bleeding.
This study conforms to the Helsinki Declaration of
1975 and was approved by the Institutional Review
Board of China Medical University Hospital (CMUH
IRB No. DMR99-IRB-240). All individuals provided
written informed consent prior to study enrollment.
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Serum markers including α2-macroglobulin, alanine
aminotransferase (ALT), apolipoprotein A1, total biliru-
bin, γ-glutamyl transpeptidase (GGT) and haptoglobin
were tested in the same laboratory, and results were
then sent to www.biopredictive.com to determine a
measure of liver fibrosis (FibroTest F score) and
necroinflammatory activity (ActiTest A score) using
patented artificial intelligence algorithms [37,38].
ARFI LSM
ARFI technology [39] was integrated into a conventional
ultrasound system (Acuson S2000 with a Siemens 4C1
curved array, 4.00 MHz for B-mode, 2.67 MHz for push
pulses and 3.08 MHz for detection pulses; Siemens Med-
ical Solutions, Mountain View, California, USA). The de-
tection pulses measured the shear wave velocity (SWV),
which was considered to directly relate to tissue
stiffness.
All ARFI stiffness measurements were performed by
the same hepatologist, who was experienced in digestive
system ultrasonography and blinded to the patient data.
The right lobe [17] of the liver (Couinaud segments VIII,
V, VII, VI) was approached intercostally [18], with the
patient lying in a dorsal decubitus position [12] with
both arms above the head and holding their breath dur-
ing virtual touch quantification (VTQ) measurements.
During each measurement, the region of interest (ROI)
(10x5 mm) was placed at the middle of the acoustic
field, avoiding large blood vessels and biliary tracts.
SWV results were recorded in meters per second
(m/s) and stored as jpg image files. Each patient
received 10 successful LSMs (failed measurements
were defined as SWV= "x.xx m/s") [40]. Reliable cases
were defined as those with an interquartile range
(IQR) of less than 30% of the median of 10 successful
LSMs, and a successful rate of LSMs greater than
60%. Other cases were deemed unreliable and excluded
[9,10,19].
Histology
Senior hepatologists performed the percutaneous right
lobe liver biopsy. All biopsy specimens were interpreted
by an expert pathologist blinded to the results of LSMs
and patient data. Biopsy specimens at least 15 mm in
length containing at least five portal tracts were defined
adequate [6]. Liver fibrosis and necroinflammatory activ-
ity were staged and graded using the METAVIR scoring
system: F0, no fibrosis; F1, portal fibrosis without septa;
F2, portal fibrosis with a few septa; F3, numerous septa
without cirrhosis; and F4, cirrhosis; A0, none; A1, mild;
A2, moderate; and A3, severe necroinflammatory activity
[41]. Steatosis categories were S0, no steatosis; S1, 1 to
5% (percentage of hepatocytes containing visiblemacrovesicular steatosis); S2, 6 to 32%; S3, 33 to 66%;
and S4, 67 to 100% [42].
Statistical analysis
The intraobserver correlations of ARFI LSM were evalu-
ated using an intraclass correlation coefficient (ICC) for
independent LSMs performed on two separate occasions
in 20 patients by the same hepatologist with experience
in 50 training cases.
Spearman’s rank correlation was used to evaluate the
significance of correlations between continuous variables
and liver fibrosis stages. Intergroup differences were ana-
lyzed using Fisher’s exact test for proportions, and the
Student’s t-test or one-way ANOVA for continuous vari-
ables, when appropriate.
Receiver operating characteristic (ROC) curves were
used to optimize the cutoff values [43] and evaluate
diagnostic performance.
After univariate linear regression, variables with a
P value of less than .25 were included in the subsequent
stepwise multiple linear regression modelling. In
addition to the two potential confounders of age
and sex, the three final multiple linear regressions
included variables maximizing the adjusted R2 in each
stepwise regression to identify significant independent
explanatory factors for LSM. Four final multiple linear
regression models were used to delineate the necroin-
flammatory effects on LSM after adjusting for serum
ALT levels (model estimates are reported in the dis-
cussion section), ALT/upper limit of normal (ULN,
40 IU/L) categories (model 1), ActiTest A scores
(model 2) and METAVIR A grades (model 3). Binary
logistic regression was also used to examine the
necroinflammatory effects on false positivity in liver fi-
brosis evaluation using ARFI LSM in patients with
METAVIR F1, F2 and F3.
Data were analyzed using SPSS version 17.0 for Micro-
soft Windows (SPSS, Chicago, Illinois, USA). A two-
sided P value of < .05 indicated statistical significance.
Results
Patients
Among the 137 patients, this study excluded 2 patients
with liver cancer (both HCC), 2 with ALD, 1 with end
stage renal disease, 2 with unreliable LSM results, and 3
with inadequate specimen quality. Thus, 127 patients
entered the complete analysis.
Age, serum ALT, total bilirubin, HCV RNA, inter-
national normalized ratio (INR) of prothrombin time,
platelet count, liver SWV, and F score of FibroTest dif-
fered significantly between the non-cirrhotic and cir-
rhotic groups (Table 1). The serum ALT levels ranged
from 14 to 488 IU/L, and Actitest A scores ranged from
0.04 to 0.97. Spearman’s rank correlation coefficients
Table 1 Patient characteristics
Variable METAVIR F0-3 METAVIR F4 P value
n = 109 n= 18




BMI, kg/m2 24.64(0.33) 24.02(0.79) .477
HCV genotype (n) 1.000
1 53 9
Non-1 56 9
HCV RNA, x 106, copies/mL 8.16(1.21) 1.02(0.52) <.001
ALT, IU/L 97.94(8.24) 64.28(8.07) .005
ALT/ULN (n) .273
<1x 26 5
≧1x <2x 35 7
≧2x <3x 21 5
≧3x <4x 7 1
≧4x 20 0
ActiTest, A score 0.51(0.03) 0.51(0.06) .928
Bilirubin, umol/L 16.80(0.54) 22.36(2.00) <.001
Cr, umol/L 71.80(4.34) 65.42(4.35) .301
INR 1.02(0.01) 1.12(0.03) <.001
Na, meq/L 137.90(0.24) 137.83(0.60) .918
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Table 1 Patient characteristics (Continued)
Liver SWV, m/s 1.65(0.06) 2.62(0.19) <.001
FibroTest, F score 0.57(0.03) 0.79(0.04) <.001
Continuous variables were presented as mean (standard error) and examined using the Student’s t test. Categorical variables were estimated using Fisher’s exact
test. ALT, serum alanine aminotransferase; Cr, serum creatinine; INR, international normalized ratio of prothrombin time; METAVIR A, activity; METAVIR F, fibrosis;
Na, serum sodium; SWV, shear wave velocity.
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stages; 0.305 (P < .001) between ActiTest A scores and
METAVIR F stages (Figure 1). Univariate linear regres-
sions were both significant between ALT and ARFI LSM
(R2 = 0.074, P= .002), and between ActiTest A scores
and ARFI LSM (R2 = 0.198, P < .001) (Figure 2).
Histology
The mean length of the included liver biopsy specimens
was 21.7± 3.3 mm (standard deviation, SD) (range, 15 to
32 mm). Using the METAVIR F scoring system, 46 patients
were staged as F1, 40 as F2, 23 as F3, and 18 as F4.
ARFI LSM
The ICC was 0.993 (95% CI, 0.981-0.997; P < .001) for
LSM. The descriptive statistics of the liver SWVs for the
METAVIR stages were as follows: F1: mean,
1.283 ± 0.037 m/s (standard error of mean, SE); median,
1.205 m/s (range, 0.96 to 2.21); F2: mean,
1.630 ± 0.081 m/s; median, 1.590 m/s (range, 0.98 to
3.28); F3: mean, 2.433 ± 0.134 m/s; median, 2.395 m/s
(range, 1.09 to 3.58); F4: mean, 2.619 ± 0.187 m/s; me-
dian, 2.525 m/s (range, 1.06 to 4.56) (Figure 3).
The Spearman’s rank correlation coefficient between
liver SWV and METAVIR F stages was 0.696 (P < .001).
The overall intergroup difference in liver SWVsFigure 1 Box plot of necroinflammatory degrees corresponding to th
coefficients were 0.196 (P= .027) between serum alanine aminotransferase
A scores and METAVIR F stages (B). Pair-wise comparisons of ActiTest A sco
P< .005.between METAVIR F1 to F4 was significant (P < .001).
Pair-wise comparisons also showed significant differ-
ences between groups: all P < .001, except P= .412 for
F3 versus F4.
To classify METAVIR F stages, the areas under the
ROC curves (AUCs) were ARFI LSM, 0.847 (95% CI,
0.779-0.914) and FibroTest, 0.823 (95% CI, 0.748-0.898),
for F1 versus F2-4; ARFI LSM, 0.902 (95% CI, 0.835-
0.970) and FibroTest, 0.812 (95% CI, 0.735-0.888), for
F1-2 versus F3-4; ARFI LSM, 0.831 (95% CI, 0.723-
0.939) and FibroTest, 0.757 (95% CI, 0.648-0.865), for
F1-3 versus F4. A comparison of the AUCs [16] using
liver SWV and FibroTest results showed insignificant
differences between the following groups: F1 versus F2-
4, P= .638; F1-2 versus F3-4, P= .086; F1-3 versus F4,
P= .341 (Figure 4).
The optimal cutoff values to classify METAVIR F
stages using ARFI LSM were 1.55 m/s for F1 versus
F2-4 (74.1% sensitivity, 87.0% specificity, 90.9% positive
predictive value (PPV), 65.6% negative predictive value
(NPV), 78.8% concordance, 21.2% discordance), 1.81 m/s
for F1-2 versus F3-4 (90.2% sensitivity, 89.5% specifi-
city, 80.4% PPV, 95.0% NPV, 89.7% concordance, 10.3%
discordance), and 1.98 m/s for F1-3 versus F4 (88.9%
sensitivity, 79.8% specificity, 42.1% PPV, 97.8% NPV,
81.1% concordance, 18.9% discordance) (Table 2).e METAVIR fibrosis (F) stages. The Spearman’s rank correlation
(ALT) levels and METAVIR F stages (A); 0.305 (P< .001) between ActiTest
res showed significant differences between groups F1, F2, and F3: all
Figure 2 Univariate linear regressions between necroinflammatory degrees and liver shear wave velocity (SWV). Univariate linear
regressions were both significant between serum alanine aminotransferase (ALT) levels and liver SWV (R2 = 0.074, P= .002) (A), and between
ActiTest A scores and liver SWV (R2 = 0.198, P< .001) (B).
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After excluding the HCV genotype (P= .810), serum cre-
atinine (Cr) (P= .997), and sodium (Na) (P= .388), univari-
ate linear regression modelling selected BMI, HCV RNA,
METAVIR F stages, ALT/ULN (40 IU/L) categories
(model 1), ActiTest A scores (model 2) and METAVIR A
grades (model 3), hepatic steatosis categories, bilirubin,
INR, and platelet count (all P< .25), in addition to ageFigure 3 Box plot of liver stiffness corresponding to the
METAVIR fibrosis (F) stages. The overall inter-group difference of
liver shear wave velocity (SWV) among METAVIR F1 to F4 was
significant (P< .001). Pair-wise comparisons also showed significant
differences between groups: all P< .001, except P= .412 for F3 versus
F4.(P= .001) and sex (P= .425), for the subsequent stepwise
multiple linear regressions. The HCV RNA, hepatic stea-
tosis categories, and serum bilirubin were excluded from
the stepwise regressions for all three models.
Finally, in addition to BMI, METAVIR F stages, and
platelet count, multiple linear regression models 1, 2,
and 3 consistently identified serum ALT/ULN categories
(model 1), ActiTest A scores (model 2) and METAVIR
A grades (model 3) as significant independent explana-
tory factors for LSM (Table 3).
Thirty-two patients out of the 109 patients with
METAVIR F1, F2 and F3 were false positive (32/109,
29%). False positive case numbers were as follows: 8 (8/
46, 17%) (ARFI LSM> 1.55 m/s) in METAVIR F1; 8 (8/
40, 25%) (LSM>1.81 m/s) in F2; 16 (16/23, 70%)
(LSM> 1.98 m/s) in F3 stages.
Using ALT levels to discriminate the false positive
(n = 32) from the non false positive (n = 77) of the 109
patients with METAVIR F1, F2 and F3, the AUC was
0.715 (SE, 0.053; 95% CI, 0.612-0.819; P < .001). The
ALT level of 109.5 IU/L was the optimal cutoff value
with a sensitivity of 56.3% and a specificity of 81.8%.
Using the ActiTest A scores, the optimal cutoff was 0.35
(AUC, 0.736; SE, 0.051; 95% CI, 0.636-0.835; P < .001;
sensitivity, 93.8%; specificity, 41.6%)(Figure 5).
Using “ALT/ULN <1x”, “METAVIR A0”, and “ActiTest
A score 0.00-0.35” as reference categories, univariate
binary logistic regressions showed significant necroin-
flammatory effects on the false positivity of LSM to stage
fibrosis in the 32 patients with METAVIR F1, F2 and F3.
“ALT/ULN ≧3x” had an odds ratio (OR) of 15.0 (95%
CI, 2.9-76.6; P= .001). “METAVIR A2-3”: OR, 32.7; 95%
CI; 6.4-166.5; P < .001. “ActiTest A score 0.36-0.75”: OR,
Figure 4 Receiver operating characteristic (ROC) curves to classify the METAVIR fibrosis stages. Two diagnostic modalities, liver shear
wave velocity (SWV), and FibroTest (F score) were compared. P value: significance for comparisons of areas under ROC curves between using liver
SWV and FibroTest.
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1.00”: OR, 11.9; 95% CI, 2.5-57.2; P= .002 (Table 4).
Discussion
In the chronically injured liver, fibrogenesis is the com-
plex dynamic interplay among various hepatic cell types
and mediators in which the process of perpetuation fol-
lows initiation [4]. With the clinical application of mag-
netic resonance (MR) and ultrasound-based LSM,
studies using MR elastography (MRE) [44], FibroScan,
and ARFI elastography have demonstrated significant
correlations between liver stiffness and liver fibrosis.
However, liver stiffness and liver fibrosis are not
equivalent.
In addition to the accumulation of the fibrotic extra-
cellular matrix, other components of chronic liver dis-
ease, including cholestasis [31,32], cardiac congestion
[33], and, particularly, the degree of necroinflammatory
activity, can exaggerate ultrasound-based LSM. Patients
with CHC usually manifest relatively stable serum ALT
levels compared with the abrupt and fluctuating ALT
levels in patients with chronic hepatitis B (CHB). Swel-
ling of hepatocytes, interstitial edema, and infiltrates of
inflammatory cells may increase liver stiffness in patientswith acute hepatitis [45]. After adjusting for other demo-
graphic and biological covariates, the results of our study
indicate that a 100 IU/L increase in serum ALT levels
augmented liver stiffness values by approximately
0.155 m/s (model R2 = 0.630, adjusted R2 = 0.602).
ActiTest is a biomarker of liver necroinflammatory
histological activity validated in patients with CHC. The
accuracy of ActiTest for grading necroinflammatory ac-
tivity in HCV-infected patients was significantly higher
than serum ALT alone [34]. In our study, the ActiTest A
score model (R2 =0.662, adjusted R2 = 0.636) was super-
ior to the models using serum ALT levels (R2 = 0.630,
adjusted R2 = 0.602), ALT/ULN categories (R2 =0.661,
adjusted R2 = 0.629) and METAVIR A grades (R2 = 0.651,
adjusted R2 = 0.620) in explaining the LSM results.
The cutoffs of ARFI LSM in this study (1.55 m/s for
F1 versus F2-4; 1.81 m/s for F1-2 versus F3-4) were in
part higher than those in the latest study on 139 CHC
cases by Rizzo et al. (1.3 m/s for F1 versus F2-4; 1.7 m/s
for F1-2 versus F3-4)[12]. Necroinflammatory effects ex-
plain most of the differences. First, the overall necroin-
flammatory degree was higher (Student’s t-test, P= .034)
in this study (mean ALT, 93.2; SE, 7.2 IU/L; n = 127)
than for Rizzo et al. (mean ALT, 77.2; SD, 33.0 IU/L;
Table 3 Three multiple linear regression models to
identify independent significant factors that explain liver
stiffness
Variable Model 1 Model 2 Model 3
B SE P B SE P B SE P
Age, year -.003 .004 .512 -.004 .004 .353 -.004 .004 .366
Male gender -.193 .084 .024 -.194 .083 .020 -.124 .085 .147
BMI, kg/m2 .032 .013 .013 .036 .012 .005 .026 .012 .041
INR .972 .572 .092 .890 .564 .117 1.146 .573 .048
Platelet, x109/L -.003 .001 .002 -.003 .001 .003 -.002 .001 .007
METAVIR
F2 .089 .113 .430 .049 .113 .666 .123 .114 .284
F3 .739 .154 <.001 .670 .155 <.001 .670 .161 <.001
F4 .989 .168 <.001 .954 .165 <.001 .892 .171 <.001
ALT/ULN
≧1<2x .307 .110 .006
≧2<3x .429 .122 .001
≧3 .523 .133 <.001
ActiTest A score .717 .163 <.001
METAVIR A
A1 .189 .100 .061
A2-3 .551 .144 <.001
R2 .661 .662 .651
adjusted R2 .629 .636 .620
Variable references: female gender, METAVIR F1, ALT/ULN <1x, METAVIR A0;
ALT, serum alanine aminotransferase; B, coefficient; INR, international
normalized ratio of prothrombin time; SE, standard error of coefficient; ULN,
upper limit of normal.
Table 2 The diagnostic performance of liver SWV and
FibroTest in classifying METAVIR fibrosis (F) stages
METAVIR
F1 vs F2-4 F1-2 vs F3-4 F1-3 vs F4
Liver SWV
AUC (95% CI) 0.847(0.779-0.914) 0.902 (0.835-0.970) 0.831 (0.723-0.939)
SE of AUC 0.034 0.035 0.055
Cutoff (m/s) 1.55 1.81 1.98
Sensitivity 74.1% 90.2% 88.9%
Specificity 87.0% 89.5% 79.8%
PPV 90.9% 80.4% 42.1%
NPV 65.6% 95.0% 97.8%
Concordance 78.8% 89.7% 81.1%
Discordance 21.2% 10.3% 18.9%
+LR 5.7 8.6 4.4
-LR 0.3 0.1 0.1
DOR(95% CI) 19.0(7.1-51.3) 79.1(22.9-273.8) 31.6(6.8-147.9)
FibroTest
AUC (95% CI) 0.823(0.748-0.898) 0.812 (0.735-0.888) 0.757 (0.648-0.865)
SE of AUC 0.038 0.039 0.055
Concordance = (true positive n + true negative n)/127, and discordance = (false
positive n + false negative n)/127; AUC, area under the receiver operating
characteristic curve; DOR, diagnostic odds ratio; LR, likelihood ratio; NPV,
negative predictive value; PPV, positive predictive value; SE, standard error;
SWV, shear wave velocity.
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tended to be more severe in METAVIR F3 and F2 than
F1 stages in this study (Figure 1). Thus, the LSM values
were more augmented in F3 and F2 than F1 stages. The
analyses of false positivity in patients with F1 to F3 also
correlated well with the necroinflammatory effects
(Table 4). Third, cirrhotic Taiwanese patients (mean age,
62.7; SE, 1.5 years; n = 18) referred to the unit for SOC
tended to be older (Student’s t-test, P= .0083) than those
in the study by Rizzo et al. (mean age, 55; SD, 12 years;
n = 139) [12]. Despite the advanced countrywide educa-
tion and health insurance coverage, these patients were
characterized by poor patient compliance and late diag-
nosis. Although age did not affect LSM significantly, as
demonstrated in models in the present and previous
studies, an older age may have resulted in significant fi-
brosis progression in these cirrhotic Taiwanese patients
despite the relatively compensated liver reserves.
Despite the variation among previous investigations,
several recent studies have demonstrated the necroin-
flammatory effects on liver stiffness by evolving analyses.
In a longitudinal study using FibroScan, Sagir et al.
[21] observed false positivity for cirrhosis (cutoff > 12.5
kPa) in 15 of 20 non-cirrhotic patients with acute liver
damage of various etiologies. In 6 patients, the LSMs
dropped below 12.5 kPa with normalized ALT levelsduring follow-up. Using a longitudinal analysis, Arena
et al. [20] demonstrated significant correlations between
sequential serum ALT levels and LSM results at different
time points. Although these studies showed the need for
caution when analyzing LSM in patients with necroin-
flammatory flares, they did not include regression esti-
mates. Seo et al. [25] demonstrated that peak ALT levels
significantly explained peak LSMs in 31 patients in acute
hepatitis A via linear regressions adjusting for age and
sex.
A cross-sectional study by Le et al. [23] showed that
LSM using FibroScan in 158 patients was independently
associated with histological necroinflammatory grading,
but irrespective of serum ALT levels. Fung et al. [26]
reported a suboptimal PPV (as low as 10%) for LSM
using FibroScan to diagnose true cirrhosis in 102
patients (median age, 41; range, 18–63 years) with active
hepatitis B (median serum ALT, 89; range, 46–501 IU/
L). Multiple logistic regressions by Myers et al. [29]
showed that serum ALT levels greater than the optimal
cutoff value 60 IU/L from ROC analysis were signifi-
cantly correlated with the discordance (at least 2 stages
between FibroScan and biopsy). Chan et al. [24] and
Figure 5 Receiver operating characteristic (ROC) curves to classify the false positivity in METAVIR F1 to F3. Using alanine
aminotransferase (ALT) levels (A) to discriminate the false positive in liver fibrosis evaluation using acoustic radiation force impulse elastography
(n = 32) from the non false positive (n = 77) of the 109 patients with METAVIR F1, F2 and F3, the area under ROC curve (AUC) was 0.715 (standard
error, SE, 0.053; 95% CI, 0.612-0.819; P< .001). The ALT level of 109.5 IU/L was the optimal cutoff value with a sensitivity of 56.3% and a specificity
of 81.8%. Using the ActiTest A scores (B), the optimal cutoff was 0.35 (AUC, 0.736; SE, 0.051; 95% CI, 0.636-0.835; P< .001; sensitivity, 93.8%;
specificity, 41.6%).
Chen et al. BMC Gastroenterology 2012, 12:105 Page 9 of 13
http://www.biomedcentral.com/1471-230X/12/105Kim et al. [27] proposed distinct sets of cutoff values
stratified by distinct ALT profiles.
Tapper et al. [30] further delineated the positive
necroinflammatory effects on LSM using FibroScan
through linear regressions in 684 HCV patients with
METAVIR F0, F1 and F2. Logistic regressions also
showed that false positivity of liver fibrosis staging was
associated with both histological and serum hepatic
necroinflammatory activity. Using 14.5 kPa as the cutoff
of cirrhosis, grade 3 inflammation had an OR of 9.10
(95% CI, 2.49-33.4). Likewise, serum levels of ALT
greater than 80 IU/L and 120 IU/L had ORs of 3.84
(95% CI, 2.10-7.00) and 4.10 (95% CI, 2.18-7.69) over
references, respectively. Yoon et al. [15] used ARFI elas-
tography to demonstrate a significant correlation (Pear-
son's r = 0.431, P < .05) between LSM values and serum
ALT levels, and a marked positive effect of histological
necroinflammatory activity on LSM. However, this study
did not adjust for other relevant essential covariates.
ARFI elastography performed potentially better for
patients with normal ALT than for those with high ALT
(AUCs, 0.88 versus 0.73 for METAVIR F1-2 versus F3-4,
0.92 versus 0.72 for F1-3 versus F4). However, AUCs
were not statistically compared. The cutoff values tended
to be lower for patients with normal ALT than for those
with high ALT levels (ALT> 40 IU/L)(1.09 versus
1.16 m/s for F1-2 versus F3-4, and 1.81 versus 2.23 m/s
for F1-3 versus F4, respectively).
In contrast to results indicating positive necroinflam-
matory effects on liver stiffness, Harata et al. [32] identi-
fied a negative correlation between serum ALT levels
and liver stiffness in patients with cholestasis. Cholesta-
sis is a condition in which the release of hydrostaticpressure with synchronous necroinflammatory activity
can, paradoxically, reduce the values of LSM using
FibroScan. Rizzo et al. [12] found distinct necroinflam-
matory effects on LSM between using FibroScan and
ARFI elastography. Colombo et al. [13] demonstrated an
insignificant (Spearman’s rank) correlation between
necroinflammation and LSM. The serum ALT specific
cutoffs of 202 CHB patients in a study by Cardoso et al.
did not increase the diagnostic performances using
FibroScan for liver fibrosis evaluation [28].
Although hepatic steatosis is prevalent in patients with
CHC, the linear regression analysis in this study did not
identify steatosis as a significant independent explanatory
factor for the ARFI LSM results. However, larger sample
sizes are required to further delineate the effects of more
severe forms of steatosis (S3, S4) on ARFI LSM results.
Motosugi et al. [46] also demonstrated the insignificance
of different ARFI LSM results among four grades of stea-
tosis (P= .9018). Using MRE in a mouse model, Yin et al.
[47] showed that steatosis did not correlate significantly
with liver stiffness at each liver fibrosis stage.
This study shows that BMI significantly and independ-
ently explain the results of ARFI LSM (Table 3). Similarly,
Roulot et al. [48] used FibroScan to show that liver stiff-
ness was significantly higher (P= .0005) in obese patients
(with BMI> 30 kg/m2) than in overweight or normal
patients, after adjusting for age, sex, ALT, aspartate amino-
transferase (AST) and ferritin. Baba et al. also demon-
strated a significant association between BMI and liver
stiffness using FibroScan. Hepatic steatosis, however, was
not evaluated in adjusted models [49]. Conversely, Tal-
walkar et al. [50] reported an insignificant (linear) correl-
ation between BMI and LSM results using MRE.
Table 4 Factors associated with false positivity in patients with METAVIR F1, F2 and F3
Variable Non FP FP OR(95% CI) P value
n = 77 n=32
Age, year 50.8(1.4) 53.4(2.0) .316
Gender, male/female (n) 35/42 16/16 .679
BMI, kg/m2 24.34(0.37) 25.37(0.68) .155
HCV genotype, 1/non-1 (n) 38/39 15/17 .836
HCV RNA, x 106, copies/mL 7.14(1.12) 10.61(3.12) .194
ALT, IU/L 83.01(9.40) 133.88(15.02) .004
ALT/ULN (n)
<1x 24 2 reference
≧1x <2x 25 10 4.8(0.9-24.2) .057
≧2x <3x 16 5 3.8(0.6-21.7) .140
≧3x 12 15 15.0(2.9-76.6) .001*
ActiTest A score (n) .
0.00-0.35 31 2 reference
0.36-0.75 24 13 8.4(1.7-40.8) .008*
0.76-1.00 22 17 11.9(2.5-57.2) .002*
Bilirubin, umol/L 15.76(0.56) 19.30(1.12) .002
Cr, umol/L 70.82(2.82) 74.14(4.55) .817
INR 1.00(0.01) 1.05(0.02) .007
Na, meq/L 137.94(0.28) 137.81(0.46) .527
Platelet, x 109/L 184.21(6.20) 158.31(9.37) .025
METAVIR F1/2/3 (n) 38/32/7 8/8/16 <.001
METAVIR A (n)
A0 28 3 reference
A1 45 15 3.1(0.8-11.7) .094
A2-3 4 14 32.7(6.4-166.5) <.001*
Hepatic steatosis S0/1/2/3/4(n) 10/28/35/3/1 5/9/17/1/0 .903
Liver SWV, m/s 1.34(0.03) 2.40(0.11) <.001
FibroTest, F score 0.51(0.03) 0.72(0.04) <.001
Thirty-two patients of the 109 patients with METAVIR F1, F2 and F3 were false positive (32/109, 29%) in liver fibrosis evaluation using acoustic radiation force
impulse elastography. False positive case numbers were: 8 (8/46, 17%) (ARFI LSM> 1.55 m/s) in METAVIR F1; 8 (8/40, 25%) (LSM> 1.81 m/s) in F2; 16 (16/23, 70%)
(LSM> 1.98 m/s) in F3 stages. Continuous variables were presented as mean (standard error) and examined using the Student’s t-test. Categorical variables were
estimated using Fisher's exact test or univariate binary logistic regression*. ALT, serum alanine aminotransferase; ARFI, acoustic radiation force impulse; CI,
confidence interval; Cr, serum creatinine; FP, false positivity; INR, international normalized ratio of prothrombin time; LSM, liver stiffness measurement; METAVIR A,
activity; METAVIR F, fibrosis; Na, serum sodium; non FP, true positive + true negative + false negative; OR, odds ratio; SWV, shear wave velocity.
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of age and sex on ARFI LSM were insignificant in this
study. Previously demonstrated as a significant factor
explaining liver fibrosis evaluation [51], platelet count was
strongly associated with ARFI LSM after adjustment, un-
like the inconsistency and insignificance of INR (Table 3).
To minimize histology bias [6,52], the percutaneous
liver biopsy in this study immediately followed ARFI
LSM. Specimens were of adequate length, and an expert
pathologist interpreted histological findings. Unreliable
cases or failed ARFI measurements were primarily
derived from obese patients with poor transient apnea
maneuvers. Thus, future studies may analyze factorsassociated with unreliable cases or failure measurements.
The present analyses show that the R2 values were mod-
est for the regression models; therefore, other potential
explanatory factors, especially direct tissue markers [45],
must be identified to construct an optimal explanatory
model (Table 3).
Future analyses would require a larger sample size to de-
velop cutoffs and perform validations that are potentially
more reliable and stable than those of this study. These
investigations may compare the diagnostic performances
of ARFI LSM with another promising diagnostic modality:
MRE. Although FibroTest was initially proposed as a simi-
lar first-line approach to histology for prediction of 5-year
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a standard of reference, in addition to METAVIR F sta-
ging, for evaluating the diagnostic value of ARFI LSM in
baseline or chronological analysis.
The limitations of this study include the lack of strati-
fication of patients with cirrhosis into compensated and
decompensated (excluded) groups. The absence of a de-
compensated group, which may have a high and broad
spectrum for LSM, may have caused the insignificant
differences in LSM results between METAVIR F3 and F4
(P= .412) before adjusting for other covariates. Further
analyses should identify optimal cutoffs for LSM to strat-
ify the broad cirrhosis category and enable risk estima-
tion of end points in chronological analyses [53]. This
study does not identify the cutoff for LSM between
METAVIR F0 and F1-F4 because of the lack of well-
established criteria for recruiting true cases with F0 fi-
brosis without liver biopsy.
Future noninvasive liver fibrosis evaluation tools
should focus on exact staging of fibrosis, rather than
classifying patients into categories of milder versus more
severe fibrosis stages. In the milder strata of liver fibro-
sis, necroinflammation can easily overwhelm the fibrotic
effects on LSM [30]. In this study, the diagnostic per-
formance of ARFI LSM was potentially limited when
distinguishing between METAVIR F1 and F2 categories
too. The insignificant regression coefficient in Table 3
reflects the potentially limited sensitivity for ARFI LSM
in distinguishing F2 from F1. Therefore, further research
is needed prior to the clinical application of ARFI LSM
for surveillance of progression, or regression, of liver fi-
brosis. The real clinical relevance between METAVIR F1
and F2 is still not known with respect to either progno-
sis or risk of disease progression over the short to inter-
mediate term of 5 to 10 years [5]. Future studies should
develop algorithms based on a combination of ARFI
LSM and essential serum markers for liver fibrosis
evaluation to minimize false positivity of fibrosis staging
[24,27,54]. A further limitation is that this study did not
perform standardization of AUCs based on the preva-
lence of liver fibrosis stages [55].
Conclusions
In conclusion, the degree of concurrent hepatic necroin-
flammatory activity independently and significantly exag-
gerated liver fibrosis evaluation using ARFI LSM.
However, comparisons of concurrent FibroTest and
ARFI LSM indicate that ARFI LSM may provide a prom-
ising alternative, or adjunctive predictive solution, for
evaluating liver fibrosis in patients with CHC.
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